Weber et al developed a second model (see previous section) for predicting early progression in a patient with asymptomatic multiple myeloma. This can help identify a patient who may require more aggressive management. The authors are from MD Anderson Cancer Center in Houston.
Patient selection: smoldering (asymptomatic) myeloma, IgG or IgA
Parameters:
(1) immunoglobulin class involved
(2) concentration of monoclonal protein
Immunoglobulin Class
Concentration
Risk Group
IgG
<= 3 g/dL
low
IgG
> 3 g/dL
intermediate
IgA
<= 3 g/dL
intermediate
IgA
> 3 g/dL
high
Risk Group
Median Time to Progression
low
52 months
intermediate
25 months
high
9 months
To read more or access our algorithms and calculators, please log in or register.
